Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein phosphatase methylesterase 1 (PPME1) is an enzyme that demethylates proteins—including the catalytic subunit of protein phosphatase 2A (PP2A)—thereby regulating PP2A activity, localization, and function. This demethylation modulates several key signaling pathways, such as the ERK pathway, and is implicated in the regulation of cell proliferation, apoptosis, and tumor progression. PME-1 is highly conserved across eukaryotes and possesses a lipase-like catalytic motif with a serine residue essential for its activity. Elevated PME-1 expression has been linked to various human cancers, with evidence of either oncogenic or tumor suppressor roles depending on the tumor context. PME-1 is considered a therapeutically relevant enzyme, but as of now, no therapies directly target it in clinical settings.
Okadaic acid: inhibits PME-1 activity, thereby preventing demethylation of PP2A subunit C. Modulators of PME-1 would theoretically alter PP2A activity by affecting the methylation state of its catalytic subunit
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein phosphatase methylesterase 1 (PPME1).